Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Nautilus Biotechnology logo
$2.61
+0.01 (+0.38%)
(As of 11/1/2024 ET)

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Key Stats

Today's Range
$2.60
$2.72
50-Day Range
$2.48
$3.08
52-Week Range
$2.19
$3.45
Volume
39,043 shs
Average Volume
74,448 shs
Market Capitalization
$327.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Consensus Rating
Moderate Buy

Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
39th Percentile Overall Score

NAUT MarketRank™: 

Nautilus Biotechnology scored higher than 39% of companies evaluated by MarketBeat, and ranked 733rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nautilus Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Nautilus Biotechnology has received no research coverage in the past 90 days.

  • Read more about Nautilus Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.65) to ($0.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nautilus Biotechnology is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nautilus Biotechnology is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nautilus Biotechnology has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nautilus Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    1.61% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.
  • Change versus previous month

  • Dividend Yield

    Nautilus Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Nautilus Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.61% of the float of Nautilus Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Nautilus Biotechnology has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.
  • Change versus previous month

  • News Sentiment

    Nautilus Biotechnology has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Nautilus Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $234,729.00 in company stock.

  • Percentage Held by Insiders

    40.50% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nautilus Biotechnology's insider trading history.
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

NAUT Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
See More Headlines

NAUT Stock Analysis - Frequently Asked Questions

Nautilus Biotechnology's stock was trading at $2.99 at the beginning of 2024. Since then, NAUT stock has decreased by 12.7% and is now trading at $2.61.
View the best growth stocks for 2024 here
.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) posted its earnings results on Tuesday, October, 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04.

Top institutional investors of Nautilus Biotechnology include China Universal Asset Management Co. Ltd. (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Sujal M Patel, Subramanian Sankar, Anna Mowry, Matthew B Murphy, Gwen E Weld, Perceptive Advisors Llc, Mary E Godwin, Matthew L Posard and Matthew S Mcilwain.
View institutional ownership trends
.

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

Last Earnings
10/29/2024
Today
11/02/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+72.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-63,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.78 per share

Miscellaneous

Free Float
74,620,000
Market Cap
$327.71 million
Optionable
Optionable
Beta
1.22
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (NASDAQ:NAUT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners